Who are ibuzatrelvir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paxlovid (Copackaged), Lonsurf, PODOFILOX, Dendrid, Elbasvir/Grazoprevir, VAL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibuzatrelvir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ibuzatrelvir — Competitive Intelligence Brief

ibuzatrelvir (ibuzatrelvir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral. Area: Infectious Disease.

marketed Antiviral SARS-CoV-2 main protease (Mpro) Infectious Disease Live · refreshed every 30 min

Target snapshot

ibuzatrelvir — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ibuzatrelvir TARGET	ibuzatrelvir	Pfizer	marketed	Antiviral	SARS-CoV-2 main protease (Mpro)
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
Dendrid	IDOXURIDINE	Novartis	marketed	Nucleoside Analog Antiviral	Thymidine kinase, cytosolic	1963-01-01
Elbasvir/Grazoprevir	Elbasvir/Grazoprevir	University of Florence	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	HCV NS5A protein and HCV NS3/4A serine protease
VAL	VAL	Estetra	marketed	Nucleoside analog antiviral	Cytomegalovirus (CMV) DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2037-02-03 — Lonsurf · 10456399 · US
2037-02-03 — Lonsurf · 10960004 · US
2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (Antiviral class)

Ain Shams University · 1 drug in this class
Arbutus Biopharma Corporation · 1 drug in this class
Australasian Gastro-Intestinal Trials Group · 1 drug in this class
Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Invivyd, Inc. · 1 drug in this class
JW Pharmaceutical · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Pfizer · 1 drug in this class
Professor Francois Venter · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ibuzatrelvir — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuzatrelvir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab